Proton radiotherapy for thymic tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, non-randomized phase II study evaluates the effectiveness of proton beam radiotherapy in patients with thymic epithelial tumors, including thymoma and thymic carcinoma, either post-surgery or inoperable with localized disease. The study aims to assess primary endpoints such as cardiac and pulmonary toxicity, as well as local control over five years. Secondary endpoints include progression-free survival, overall survival, quality of life, and relapse patterns. Patients who are not suitable for proton treatment will be monitored after receiving standard photon therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological or cytological diagnosis of thymoma or thymic carcinoma.
* With radical surgery: stage III and IVa and selected stage II with type B2, B3 and thymic carcinoma according to local routine. With non-radical surgery (R1 or R2) or inoperable patient/ patient refusing surgery: stage I - IVa, any histology
* PS WHO 0 - 2.
* FEV1 \> 1L or \>40 % of predicted and CO diffusion capacity \> 40% of predicted (postoperative measures)
* Age \>18 years, no upper age limit.
* Written informed consent from patients.

Exclusion Criteria:

* Masaoka-Koga stage IVb (distant metastases).
* Pregnancy.
* Serious concomitant systemic disorder incompatible with the study.
* Tumour motion \> 0.5 cm on two repeated 4DCT

Where it's running

• Department of Oncology, Norrlands Universitetssjukhus
  Umeå, Norrland, Sweden Recruiting
• Department of Oncology, Sahlgrenska University Hospital
  Gothenburg, Västra Götaland County, Sweden Recruiting
• Department of Oncology, Karolinska University Hospital
  Stockholm, Stockholm County, Sweden Not yet recruiting

Study contacts

• Study coordinator: Jan Nyman, Ass.prof.
• Email: jan.nyman@oncology.gu.se
• Phone: +46313421000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Pharmacogenomic panel to predict chemotherapy- and immunotherapy-induced heart damage

  A pharmacogenomic and pharmacoepigenetic panel is being tested to see if it can predict which breast cancer patients will develop heart damage from chemotherapy or immunotherapy.

  Recruiting Beneficência Portuguesa de São Paulo · Fortaleza, Ceará and 5 other locations · NCT07663357

• Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer

  This study tests whether heart changes seen on ultrasound and blood biomarkers can detect early heart problems in women receiving standard chemotherapy and anti-HER2 therapy for early breast cancer.

  Recruiting Gazi University · Ankara, Ankara · NCT07588425

• Serial contrast cardiac MRI and biomarker testing to detect anthracycline-related heart damage

  This study tries to see if repeated contrast cardiac MRI plus blood, urine, and stool biomarker checks can find early heart damage in people getting anthracycline chemotherapy.

  Recruiting Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Stuttgart · NCT07528586

• Early detection of heart and blood vessel damage from cancer treatments in children and young adults

  This project tests whether newer heart and vessel imaging and stiffness tests can find treatment-related damage earlier in children, adolescents, and young adult cancer patients.

  Recruiting at 5 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna and 4 other locations · NCT07382141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.